| CAS NO: | 173903-47-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 265.25 |
|---|---|
| Formula | C10H7N3O4S |
| CAS No. | 173903-47-4 (Tizoxanide, the active metabolite of nitazoxanide); |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 27 mg/mL (101.8 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES Code | O=C(NC1=NC=C([N+]([O-])=O)S1)C2=CC=CC=C2O |
| Synonyms | Desacetylnitazoxanide; Desacetyl nitazoxanide Desacetyl-nitazoxanide; NSC-697856; NSC697856; NSC697856 |
| In Vitro | In vitro activity: Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. IC50 value: Target: Antiviral agent in vitro: Tizoxanide inhibited virus replication of all CIVs with 50% and 90% inhibitory concentrations ranging from 0.17 to 0.21 μM and from 0.60 to 0.76 μM, respectively. Nitazoxanide and its primary metabolite, tizoxanide, inhibit hepatitis C virus (HCV) replication in HCV replicon systems. Interestingly, serial passage in nitazoxanide or tizoxanide resulted in increased sensitivity to alpha interferon 2b: EC(50)s and EC(90)s were reduced three- and eightfold, respectively. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Nitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy. |
| Animal model | |
| Formulation & Dosage | |
| References | Antiviral Res. 2008 Jan;77(1):56-63; Antimicrob Agents Chemother. 1998 Aug;42(8):1959-65; Clin Infect Dis. 2005 Apr 15;40(8):1173-80; J Antimicrob Chemother. 2002 Jan;49(1):103-11. |
m.cnreagent.com